- Home
- SLN vs SLQT Comparison
SLN vs SLQT Comparison
Compare SLN & SLQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- SLQT
- Stock Information
- Founded
- SLN 1994
- SLQT 1999
- Country
- SLN United Kingdom
- SLQT United States
- Employees
- SLN N/A
- SLQT N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- SLQT Specialty Insurers
- Sector
- SLN Health Care
- SLQT Finance
- Exchange
- SLN Nasdaq
- SLQT Nasdaq
- Market Cap
- SLN 345.3M
- SLQT 362.3M
- IPO Year
- SLN N/A
- SLQT 2020
- Fundamental
- Price
- SLN $6.24
- SLQT $2.13
- Analyst Decision
- SLN Buy
- SLQT Hold
- Analyst Count
- SLN 6
- SLQT 2
- Target Price
- SLN $39.67
- SLQT $4.38
- AVG Volume (30 Days)
- SLN 213.8K
- SLQT 947.0K
- Earning Date
- SLN 11-07-2025
- SLQT 11-06-2025
- Dividend Yield
- SLN N/A
- SLQT N/A
- EPS Growth
- SLN N/A
- SLQT N/A
- EPS
- SLN N/A
- SLQT 0.01
- Revenue
- SLN $27,169,000.00
- SLQT $1,526,594,000.00
- Revenue This Year
- SLN N/A
- SLQT $13.98
- Revenue Next Year
- SLN N/A
- SLQT $9.54
- P/E Ratio
- SLN N/A
- SLQT $159.78
- Revenue Growth
- SLN 22.28
- SLQT 15.50
- 52 Week Low
- SLN $1.97
- SLQT $1.62
- 52 Week High
- SLN $18.24
- SLQT $6.86
- Technical
- Relative Strength Index (RSI)
- SLN 46.82
- SLQT 57.81
- Support Level
- SLN $7.06
- SLQT $1.91
- Resistance Level
- SLN $7.39
- SLQT $2.22
- Average True Range (ATR)
- SLN 0.58
- SLQT 0.11
- MACD
- SLN -0.12
- SLQT 0.01
- Stochastic Oscillator
- SLN 21.87
- SLQT 76.32
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.